TEL AVIV, Israel, Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the second quarter ended June 30, 2016.
Highlights and achievements during second quarter of 2016 and to date:
Submission of regulatory filings to initiate Phase 2a study in pancreatic cancer for BL-8040 in combination with Merck's KEYTRUDA®, under immuno-oncology collaboration with Merck announced earlier this year
Signing of additional immuno-oncology collaboration, this time with MD Anderson Cancer Center, for second Phase 2a study in pancreatic cancer for BL-8040 in combination with Merck's KEYTRUDA
Continued enrollment in large (n=194), randomized Phase 2b study for BL-8040 as consolidation treatment for AML patients following standard induction treatment
Commercial launch of BL-5010 as OTC treatment for non-surgical removal of skin lesions by Omega Pharma (a division of Perrigo), following CE Mark approval in March
In-licensing of liver fibrosis project under Novartis collaboration
Philip A. Serlin appointed Chief Executive Officer, effective October 2016
Highlights and achievements during second quarter of 2016 and to date:
Submission of regulatory filings to initiate Phase 2a study in pancreatic cancer for BL-8040 in combination with Merck's KEYTRUDA®, under immuno-oncology collaboration with Merck announced earlier this year
Signing of additional immuno-oncology collaboration, this time with MD Anderson Cancer Center, for second Phase 2a study in pancreatic cancer for BL-8040 in combination with Merck's KEYTRUDA
Continued enrollment in large (n=194), randomized Phase 2b study for BL-8040 as consolidation treatment for AML patients following standard induction treatment
Commercial launch of BL-5010 as OTC treatment for non-surgical removal of skin lesions by Omega Pharma (a division of Perrigo), following CE Mark approval in March
In-licensing of liver fibrosis project under Novartis collaboration
Philip A. Serlin appointed Chief Executive Officer, effective October 2016
